|
|
|
| Study on the correlation between TIMP1 gene expression and prognosis and immunoinfiltration in colorectal cancer |
| WANG Xinjun1 HUANG Yixin2 |
1.Clinical Medical Research Center, the Affiliated Hospital of Guizhou Medical University, Guizhou Province, Guiyang 550004, China;
2.Department of Anorectal Surgery, the Affiliated Hospital of Guizhou Medical University, Guizhou Province, Guiyang 550004, China |
|
|
|
Abstract Objective To explore the correlation between TIMP1 gene expression and prognosis and immune invasion of colorectal cancer. Methods RNA expression data from the Cancer Genome Atlas (TCGA) database were used to analyze the correlation between the expression level of TIMP1 gene and clinicopathologic features of colorectal cancer patients, and to analyze the expression of TIMP1 in colorectal cancer tumors and normal tissues. Kaplan-Meier survival analysis and Cox regression were used to analyze the correlation between TIMP1 and prognosis. Gene set enrichment analysis (GSEA) and single sample gene set enrichment analysis (ssGSEA) were used to study the enrichment pathway and function of TIMP1, and association analysis of immune cell infiltration was performed. Results TIMP1 was highly expressed in colorectal cancer and was associated with poor prognosis in patients with colorectal cancer. ECM pathway, MAPK pathway and immune-related pathway might be key pathways for TIMP1 regulation. Meanwhile, the expression of TIMP1 in colorectal cancer was related to the level of immune invasion. Conclusion TIMP1 can be a potential therapeutic target and prognostic biomarker for colorectal cancer.
|
|
|
|
|
|
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Batra J，Robinson J，Soares AS，et al. Matrix metalloproteinase-10 （MMP-10） interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2：binding studies and crystal structure [J]. J Biol Chem，2012，287（19）：15935- 15946.
[3] Hawthorn L，Stein L，Varma R，et al. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma [J]. Head Neck，2004，26（12）：1069-1083.
[4] Li Z，Jing Q，Wu L，et al. The prognostic and diagnostic value of tissue inhibitor of metalloproteinases gene family and potential function in gastric cancer [J]. J Cancer，2021，12（13）：4086-4098.
[5] Wurtz SO，Schrohl AS，Mouridsen H，et al. TIMP-1 as a tumor marker in breast cancer--an update [J]. Acta Oncol，2008，47（4）：580-590.
[6] Zurac S，Neagu M，Constantin C，et al. Variations in the expression of TIMP1，TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors [J]. Oncol Lett，2016，11（5）：3354-3360.
[7] Bindea G，Mlecnik B，Tosolini M，et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer [J]. Immunity，2013，39（4）：782-795.
[8] Finotello F，Trajanoski Z. Quantifying tumor-infiltrating immune cells from transcriptomics data [J]. Cancer Immunol Immunother，2018，67（7）：1031-1040.
[9] Grunwald B，Schoeps B，Kruger A. Recognizing the Molecular Multifunctionality and Interactome of TIMP-1 [J]. Trends Cell Biol，2019，29（1）：6-19.
[10] Cruz-Munoz W，Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis [J]. Crit Rev Clin Lab Sci，2008，45（3）：291-338.
[11] Egeblad M，Werb Z. New functions for the matrix metalloproteinases in cancer progression [J]. Nat Rev Cancer，2002，2（3）：161-174.
[12] Wang P，Yang X，Zhou N，et al. Identifying a Potential Key Gene，TIMP1，Associated with Liver Metastases of Uveal Melanoma by Weight Gene Co-Expression Network Analysis [J]. Onco Targets Ther，2020，13：11923-11934.
[13] Schrohl AS，Holten-Andersen MN，Peters HA，et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer [J]. Clin Cancer Res，2004，10（7）：2289-2298.
[14] Gouyer V，Conti M，Devos P，et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent [J]. Cancer，2005，103（8）：1676- 1684.
[15] Honkavuori M，Talvensaari-Mattila A，Puistola U，et al. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma [J]. Anticancer Res，2008，28（5A）：2715-2719.
[16] Roy R，Zurakowski D，Wischhusen J，et al. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies [J]. Br J Cancer，2014，111（9）：1772-1779.
[17] Jackson HW，Defamie V，Waterhouse P，et al. TIMPs：versatile extracellular regulators in cancer [J]. Nat Rev Cancer，2017，17（1）：38-53.
[18] Song G，Xu S，Zhang H，et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway [J]. J Exp Clin Cancer Res，2016，35（1）：148.
[19] Cheng G，Fan X，Hao M，et al. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer [J]. Mol Cancer，2016，15（1）：30.
[20] Xiao W，Wang L，Howard J，et al. TIMP-1-Mediated Che- moresistance via Induction of IL-6 in NSCLC [J]. Cancers （Basel），2019，11（8）：1184.
[21] Ai L，Xu A，Xu J. Roles of PD-1/PD-L1 Pathway：Signaling，Cancer，and Beyond [J]. Adv Exp Med Biol，2020， 1248：33-59.
[22] Malik A，Sharma D，Zhu Q，et al. IL-33 regulates the IgA- microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis [J]. J Clin Invest，2016，126（12）：4469-4481.
[23] Cicalese L，Duerr RH，Nalesnik MA，et al. Decreased mucosal IgA levels in ileum of patients with chronic ulcerative colitis [J]. Dig Dis Sci，1995，40（4）：805-811.
[24] Zhang X，Liang Y. Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma：A Study Based on TCGA Data [J]. Biomed Res Int，2021，2021：8197936.
[25] Bindea G，Mlecnik B，Tosolini M，et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer [J]. Immunity，2013，39（4）：782-795. |
|
|
|
